Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 7/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23134531 | 0.85 | CYP1A2 (0.46) | EPHX2EPHX1AOC3CYP1A2TDP1 | |
| SCHEMBL85149 | 0.77 | CYP1A2 (0.50) | EPHX2EPHX1CYP1A2TDP1 | |
| SCHEMBL29324905 | 0.77 | KDM4E (0.41) | EPHX2EPHX1AOC3CYP1A2TDP1 | |
| SCHEMBL10059953 | 0.75 | EPHX2 (0.39) | EPHX2EPHX1AOC3CYP1A2TDP1 | |
| SCHEMBL13331563 | 0.74 | CYP1A2 (0.41) | EPHX2EPHX1CYP1A2TDP1 | |
| SCHEMBL10025974 | 0.72 | TP53 (0.45) | EPHX2EPHX1MAPTHTT | |
| SCHEMBL23134528 | 0.72 | MAPT (0.38) | EPHX2EPHX1AOC3CYP1A2TDP1 | |
| SCHEMBL6043112 | 0.71 | CYP1A2 (0.44) | EPHX2EPHX1CYP1A2TDP1 | |
| SCHEMBL23134625 | 0.71 | CHRM3 (0.40) | EPHX2EPHX1CYP1A2TDP1MAPT | |
| SCHEMBL19011541 | 0.71 | EPHX2 (0.49) | EPHX2EPHX1CYP1A2TDP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077794-A1 | BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS | GLAXSMITHKLINE LLC (US) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077794-A1 | BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS | MCHR1, MCHR2, MC1R | EPHX2 3338/4885EPHX1 1940/4885AOC3 959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.